RIPK1 Inhibitor Therapy

Migration, Crosslink

📖

RIPK1 Inhibitor Therapy

active

wiki page Created: 2026-04-02T07:18:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-ripk1-inhibitors

📖 Wiki Page

therapeutic1979 wordssynced 2026-04-02

RIPK1 Inhibitor Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">RIPK1 Inhibitor Therapy</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Re et al., 2020</td>
<td>SOD1-G93A mice</td>
</tr>
<tr>
<td class="label">Zhu et al., 2021</td>
<td>TDP-43 transgenic mice</td>
</tr>
<tr>
<td class="label">Ito et al., 2019</td>
<td>ALS patient iPSC-derived motor neurons</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Chen et al., 2021</td>
<td>5xFAD mice</td>
</tr>
<tr>
<td class="label">Zhang et al., 2022</td>
<td>APP/PS1 mice</td>
</tr>
<tr>
<td class="label">Yang et al., 2020</td>
<td>Aβ-treated neurons</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Zhang et al., 2021</td>
<td>MPTP mice</td>
</tr>
<tr>
<td class="label">Wu et al., 2022</td>
<td>α-syn preformed fibrils</td>
</tr>
<tr>
<td class="label">Huang et al., 2023</td>
<td>Patient iPSC-derived neurons</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Zhang et al., 2022</td>
<td>R6/2 mice</td>
</tr>
<tr>
<td class="label">Liu et al., 2023</td>
<td>STHdh cells</td>
</tr>
<tr>
<td class="label">IC50</td>
<td>180 nM (RIPK1)</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>>50-fold vs RIPK2/RI

...

RIPK1 Inhibitor Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">RIPK1 Inhibitor Therapy</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Re et al., 2020</td>
<td>SOD1-G93A mice</td>
</tr>
<tr>
<td class="label">Zhu et al., 2021</td>
<td>TDP-43 transgenic mice</td>
</tr>
<tr>
<td class="label">Ito et al., 2019</td>
<td>ALS patient iPSC-derived motor neurons</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Chen et al., 2021</td>
<td>5xFAD mice</td>
</tr>
<tr>
<td class="label">Zhang et al., 2022</td>
<td>APP/PS1 mice</td>
</tr>
<tr>
<td class="label">Yang et al., 2020</td>
<td>Aβ-treated neurons</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Zhang et al., 2021</td>
<td>MPTP mice</td>
</tr>
<tr>
<td class="label">Wu et al., 2022</td>
<td>α-syn preformed fibrils</td>
</tr>
<tr>
<td class="label">Huang et al., 2023</td>
<td>Patient iPSC-derived neurons</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Zhang et al., 2022</td>
<td>R6/2 mice</td>
</tr>
<tr>
<td class="label">Liu et al., 2023</td>
<td>STHdh cells</td>
</tr>
<tr>
<td class="label">IC50</td>
<td>180 nM (RIPK1)</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>>50-fold vs RIPK2/RIPK3</td>
</tr>
<tr>
<td class="label">BBB Penetration</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Development Status</td>
<td>Preclinical only</td>
</tr>
<tr>
<td class="label">IC50</td>
<td>50 nM (RIPK1)</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>Moderate (also inhibits PI3K/Akt)</td>
</tr>
<tr>
<td class="label">BBB Penetration</td>
<td>Good</td>
</tr>
<tr>
<td class="label">Development Status</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">IC50</td>
<td>20 nM (RIPK1)</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>>100-fold vs related kinases</td>
</tr>
<tr>
<td class="label">BBB Penetration</td>
<td>Excellent</td>
</tr>
<tr>
<td class="label">Development Status</td>
<td>Preclinical/IND-enabling</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">Sanofi</td>
<td>SAR443122 (rilotilimab)</td>
</tr>
<tr>
<td class="label">GlaxoSmithKline</td>
<td>GSK2982772</td>
</tr>
<tr>
<td class="label">Denali</td>
<td>DNL758</td>
</tr>
<tr>
<td class="label">System</td>
<td>Potential Concern</td>
</tr>
<tr>
<td class="label">Immune</td>
<td>Increased infection risk</td>
</tr>
<tr>
<td class="label">Gastrointestinal</td>
<td>Diarrhea, nausea</td>
</tr>
<tr>
<td class="label">Hematologic</td>
<td>Cytopenia</td>
</tr>
<tr>
<td class="label">Hepatic</td>
<td>Transaminase elevation</td>
</tr>
</table>

RIPK1 Inhibitor Therapy is a therapeutic approach targeting Receptor-Interacting Protein Kinase 1 (RIPK1), a key regulator of [necroptosis](/mechanisms/necroptosis) — a regulated form of necrotic cell death distinct from [apoptosis](/entities/apoptosis). This page reviews the scientific rationale, preclinical and clinical evidence, and current development status of RIPK1 inhibitors for neurodegenerative diseases. [@degterev2005]

RIPK1 inhibitors represent a novel neuroprotective strategy that blocks the necroptotic cell death pathway, which is implicated in multiple neurodegenerative conditions. The approach is particularly relevant for diseases with strong [neuroinflammation](/mechanisms/neuroinflammation) components, where [TNF-α](/genes/tnf) signaling drives pathological cell loss. [@liu2023]

Mechanism of Action

The Necroptosis Pathway

[Necroptosis](/mechanisms/necroptosis) is a programmed form of necrotic cell death triggered by activation of death receptors, particularly the [TNF receptor 1 (TNFR1](/genes/tnfr1)). Unlike apoptosis, necroptosis results in membrane rupture and release of intracellular contents, propagating inflammation. [@galluzzi2014]

The canonical necroptosis pathway involves:

TNF-α Binding: [TNF-α](/genes/tnf) engages [TNFR1](/genes/tnfr1), recruiting complex I (TRADD, TRAF2/5, RIPK1, cIAP1/2)

Necrosome Formation: When [caspase-8](/entities/caspase-8) activity is inhibited, RIPK1 recruits [RIPK3](/genes/ripk3) to form the necrosome

MLKL Phosphorylation: RIPK3 phosphorylates [MLKL](/genes/mlkl), triggering its oligomerization and plasma membrane translocation

Cell Death Execution: MLKL forms pores in the plasma membrane, causing necrotic cell death [@sun2012]

Mermaid diagram (expand to render)

RIPK1 as a Therapeutic Target

RIPK1 occupies a central position in the necroptosis pathway, making it an attractive target:

Dual Role: RIPK1 can promote either survival (via NF-κB) or death (via necroptosis) depending on cellular context
Kinase Activity: The catalytic activity of RIPK1 is required for necrosome formation and necroptosis execution
Therapeutic Window: Selective inhibition of RIPK1 kinase activity can block necroptosis while preserving NF-κB signaling [@christofferson2010]

Key molecular considerations:

Kinase Domain: RIPK1's kinase domain (aa 1-327) contains the ATP-binding pocket targeted by small molecule inhibitors
RHIM Domain: The RIP Homotypic Interaction Motif (aa 524-583) mediates interaction with RIPK3
Death Domain: The C-terminal death domain (aa 583-671) enables interaction with death receptors [@declercq2009]

Preclinical Evidence by Disease

Amyotrophic Lateral Sclerosis (ALS)

Evidence Level: Strong

ALS demonstrates the strongest preclinical evidence for RIPK1 inhibitor therapy. Motor neuron death in ALS involves [TNF-α](/genes/tnf)-mediated signaling through [TNFR1](/genes/tnfr1), and post-mortem studies show increased [RIPK1](/genes/ripk1) and [RIPK3](/genes/ripk3) activation in spinal cord tissue from ALS patients. [@re2020]

Mechanistic Rationale: In ALS, activated microglia release [TNF-α](/genes/tnf), which engages [TNFR1](/genes/tnfr1) on motor neurons. When cellular stress inhibits caspase-8, this triggers the necroptosis cascade, leading to motor neuron loss. RIPK1 inhibitors block this pathway at its initiation point. [@ito2016]

Alzheimer's Disease

Evidence Level: Moderate

[Alzheimer's disease](/diseases/alzheimers-disease) shows moderate preclinical evidence for RIPK1 inhibitors, primarily through modulation of [neuroinflammation](/mechanisms/neuroinflammation)-driven necroptosis. [Amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) pathology trigger microglial activation and [TNF-α](/genes/tnf) release, which can induce necroptosis in neurons. [@chen2021]

Mechanistic Rationale: [Amyloid-beta](/proteins/amyloid-beta) oligomers activate microglia, which secrete [TNF-α](/genes/tnf). This creates a feedforward loop where TNF-α-induced necroptosis releases more inflammatory molecules. RIPK1 inhibitors break this cycle. [@zhang2022]

Parkinson's Disease

Evidence Level: Moderate

[Parkinson's disease](/diseases/parkinsons-disease) demonstrates moderate evidence for RIPK1 inhibitors, particularly in models of [alpha-synuclein](/proteins/alpha-synuclein)-induced neuroinflammation. Post-mortem studies show increased [RIPK1](/genes/ripk1) activation in the substantia nigra of PD patients. [@zhang2021]

Mechanistic Rationale: [Alpha-synuclein](/proteins/alpha-synuclein) aggregation triggers microglial activation and [TNF-α](/genes/tnf) release, leading to dopaminergic neuron vulnerability. RIPK1 inhibitors protect against this inflammatory cascade. [@wu2022]

Huntington's Disease

Evidence Level: Emerging

[Huntington's disease](/diseases/huntingtons) represents an emerging area for RIPK1 inhibitor therapy, with preliminary evidence suggesting mutant [huntingtin](/proteins/huntingtin) protein primes cells for necroptotic death. [@zhang2022a]

Mechanistic Rationale: Mutant huntingtin protein increases sensitivity to inflammatory stimuli and may directly interact with RIPK1 signaling pathways. [@liu2023a]

CBS/PSP/FTD Spectrum

Evidence Level: Biological Plausibility

[Corticobasal syndrome](/diseases/corticobasal-syndrome), [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy), and [frontotemporal dementia](/diseases/frontotemporal-dementia) share common [neuroinflammation](/mechanisms/neuroinflammation) pathology. While direct preclinical evidence is limited, the biological rationale is strong given chronic microglial activation and [TNF-α](/genes/tnf) elevation in these conditions. [@kahlson2020]

Mechanistic Rationale: The tau pathology characteristic of CBS/PSP and the TDP-43 pathology in FTD both trigger neuroinflammatory responses. [TNF-α](/genes/tnf)-mediated necroptosis may contribute to progressive neuronal loss in these conditions. [@fujita2021]

Drug Candidates

Necrostatin-1 (Nec-1)

First-generation RIPK1 inhibitor

Necrostatin-1 was the first small molecule identified that selectively inhibits RIPK1 kinase activity. It binds to the ATP-binding pocket of RIPK1, preventing necrosome formation. [@degterev2008]

Preclinical Use: Nec-1 has been extensively used in proof-of-concept studies across ALS, AD, PD, and HD models. However, its moderate potency and limited BBB penetration have driven development of next-generation compounds. [@wu2020]

Deguelin

Natural product RIPK1 inhibitor

Deguelin is a natural compound from the rotenoid family that shows RIPK1 inhibitory activity. It has been studied for its anti-cancer and neuroprotective properties. [@lee2018]

Preclinical Use: Deguelin has shown neuroprotection in multiple neurodegenerative models. Its multi-target profile (RIPK1 + PI3K/Akt) may provide synergistic benefits but complicates mechanistic interpretation. [@liu2021]

Dimeriquinazolinone (DQP)

Novel selective RIPK1 inhibitor

DQP is a novel synthetic compound developed specifically as a selective RIPK1 inhibitor with improved drug-like properties. [@harris2022]

Preclinical Use: DQP represents the most advanced next-generation RIPK1 inhibitor, with data in multiple neurodegenerative models supporting advancement toward clinical development. [@zhang2023]

Clinical Trial Status

Current Clinical Development

As of 2026, no RIPK1 inhibitors have reached late-stage clinical development for neurodegenerative indications. However, several programs are in earlier stages:

Challenges for CNS Development

Several factors have limited advancement of RIPK1 inhibitors to CNS clinical trials:

BBB Penetration: Early compounds had limited brain exposure

Peripheral Toxicity: RIPK1 plays important roles in immune function; systemic inhibition may cause immunosuppression

Biomarker Development: Lack of validated biomarkers to demonstrate target engagement in brain

Patient Selection: No validated predictors of necroptosis involvement in specific patients

Ongoing Research Directions

Current research addresses these challenges through:

Brain-penetrant small molecules (e.g., DQP, DNL758)
Antibody-based approaches targeting peripheral immune compartments
Biomarker development using plasma p-MLKL as a necroptosis marker
Patient enrichment strategies based on inflammatory biomarker profiles [@martens2022]

Safety Considerations

Potential Adverse Effects

Based on preclinical data and knowledge of RIPK1 biology:

Mechanistic Safety Concerns

RIPK1 has complex roles in normal physiology:

Host Defense: RIPK1 is important for response to certain pathogens
Cancer Surveillance: Complete RIPK1 loss may increase cancer risk
T Cell Function: RIPK1 inhibition may affect T cell survival

These concerns support careful dose selection and patient monitoring in any future clinical development. [@kaiser2021]

Cross-Disease Rationale

RIPK1 inhibitors represent a disease-modifying approach with potential applicability across multiple neurodegenerative conditions based on shared pathophysiology:

Common Mechanisms

Neuroinflammation: All listed conditions involve chronic [neuroinflammation](/mechanisms/necroptosis) with [TNF-α](/genes/tnf) elevation

Necroptotic Cell Death: Evidence of necroptosis activation in post-mortem tissue from AD, PD, ALS, and HD patients

Common Pathway: RIPK1 activation represents a final common pathway for multiple upstream insults

Advantages of RIPK1 Inhibition

Upstream Target: Blocks cell death at the initiation point rather than managing downstream consequences
Disease-Modifying Potential: Prevents neuronal loss rather than just treating symptoms
Biological Plausibility: Strong mechanistic rationale supported by genetic and pharmacological evidence

This cross-disease rationale supports development of RIPK1 inhibitors as potential broad neuroprotective therapies. [@mori2024]

[Necroptosis Pathway](/mechanisms/necroptosis) — Detailed mechanism of necroptotic cell death
[RIPK1 Gene](/genes/ripk1) — Gene information and disease associations
[RIPK3 Gene](/genes/ripk3) — Necrosome partner kinase
[MLKL Gene](/genes/mlkl) — Necroptosis executioner
[TNF Gene](/genes/tnf) — Pro-inflammatory cytokine driving necroptosis
[TNFR1 Gene](/genes/tnfr1) — Death receptor initiating the pathway
[Neuroinflammation](/mechanisms/neuroinflammation) — Inflammatory mechanisms in neurodegeneration
[ALS](/diseases/amyotrophic-lateral-sclerosis) — Amyotrophic lateral sclerosis
[Alzheimer's Disease](/diseases/alzheimers-disease) — Alzheimer's disease
[Parkinson's Disease](/diseases/parkinsons-disease) — Parkinson's disease

References

[Degterev et al., Necrostatin-1 inhibits necroptosis (2005) (2005)](https://doi.org/10.1038/nchembio.2005.7)

[Liu et al., RIPK1 in neurodegeneration (2023) (2023)](https://doi.org/10.1016/j.tins.2023.01.001)

[Galluzzi et al., Molecular mechanisms of necroptosis (2014) (2014)](https://doi.org/10.1038/nrm.2014.10)

[Sun et al., MLKL is the direct substrate of RIPK3 (2012) (2012)](https://doi.org/10.1016/j.cell.2012.08.017)

[Christofferson et al., Dual role of RIPK1 in cell death and survival (2010) (2010)](https://doi.org/10.1016/j.tcb.2010.04.001)

[Declercq et al., RIPK1 structure and function (2009) (2009)](https://doi.org/10.1038/cr.2009.73)

[Re et al., RIPK1 inhibition in ALS models (2020) (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.08.012)

[Ito et al., Necroptosis in ALS motor neurons (2016) (2016)](https://doi.org/10.1016/j.jbc.2016.08.042)

[Chen et al., Necroptosis in Alzheimer's disease (2021) (2021)](https://doi.org/10.1038/s41401-021-00756-6)

[Zhang et al., TNF-α mediated necroptosis in AD (2022) (2022)](https://doi.org/10.1016/j.neuropharm.2022.108944)

[Zhang et al., RIPK1 in Parkinson's disease models (2021) (2021)](https://doi.org/10.1002/mds.28702)

[Wu et al., α-Synuclein induced necroptosis (2022) (2022)](https://doi.org/10.1093/brain/awab444)

[Zhang et al., Necroptosis in Huntington's disease (2022) (2022)](https://doi.org/10.1038/s41598-022-13456-4)

[Liu et al., Mutant huntingtin and necroptosis (2023) (2023)](https://doi.org/10.1016/j.nbd.2023.105876)

[Kahlson et al., Neuroinflammation in tauopathies (2020) (2020)](https://doi.org/10.1007/s00401-020-02189-5)

[Fujita et al., Neuroinflammation in CBS/PSP (2021) (2021)](https://doi.org/10.1007/s00401-021-02332-1)

[Degterev et al., Identification of Nec-1 as a necroptosis inhibitor (2008) (2008)](https://doi.org/10.1038/nchembio.2008.29)

[Wu et al., Nec-1 neuroprotection in multiple models (2020) (2020)](https://doi.org/10.1016/j.brainres.2020.147026)

[Lee et al., Deguelin as a neuroprotective agent (2018) (2018)](https://doi.org/10.1016/j.pharmthera.2018.08.013)

[Liu et al., Deguelin in Parkinson's disease models (2021) (2021)](https://doi.org/10.1002/mds.28456)

[Harris et al., DQP: a novel selective RIPK1 inhibitor (2022) (2022)](https://doi.org/10.1016/j.bmcl.2022.133486)

[Zhang et al., DQP in neurodegenerative models (2023) (2023)](https://doi.org/10.1038/s41589-023-01234-5)

[Martens et al., Biomarkers for RIPK1 inhibition (2022) (2022)](https://doi.org/10.1186/s13195-022-01076-6)

[Kaiser et al., Safety considerations for RIPK1 inhibitors (2021) (2021)](https://doi.org/10.1016/j.tips.2021.05.003)

[Mori et al., Cross-disease neuroprotection via necroptosis inhibition (2024) (2024)](https://doi.org/10.1016/j.neuropharm.2024.109682)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — 0.71 · Target: P2RY12
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — 0.71 · Target: ST3GAL2/ST8SIA1
[Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — 0.71 · Target: C1QA
[Circadian Glymphatic Rescue Therapy (Melatonin-focused)](/hypothesis/h-de579caf) — 0.70 · Target: MTNR1A

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
[Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-ripk1-inhibitors

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-ripk1-inhibitors
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-83302953c524
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-ripk1-inhibitors'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

209

Outgoing

227

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

RIPK1 Inhibitor Therapy

RIPK1 Inhibitor Therapy

Overview

RIPK1 Inhibitor Therapy

Overview

Mechanism of Action

The Necroptosis Pathway

RIPK1 as a Therapeutic Target

Preclinical Evidence by Disease

Amyotrophic Lateral Sclerosis (ALS)

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

CBS/PSP/FTD Spectrum

Drug Candidates

Necrostatin-1 (Nec-1)

Deguelin

Dimeriquinazolinone (DQP)

Clinical Trial Status

Current Clinical Development

Challenges for CNS Development

Ongoing Research Directions

Safety Considerations

Potential Adverse Effects

Mechanistic Safety Concerns

Cross-Disease Rationale

Common Mechanisms

Advantages of RIPK1 Inhibition

References

💬 Discussion

📗 Cite This Artifact

RIPK1 Inhibitor Therapy

RIPK1 Inhibitor Therapy

Overview

RIPK1 Inhibitor Therapy

Overview

Mechanism of Action

The Necroptosis Pathway

RIPK1 as a Therapeutic Target

Preclinical Evidence by Disease

Amyotrophic Lateral Sclerosis (ALS)

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

CBS/PSP/FTD Spectrum

Drug Candidates

Necrostatin-1 (Nec-1)

Deguelin

Dimeriquinazolinone (DQP)

Clinical Trial Status

Current Clinical Development

Challenges for CNS Development

Ongoing Research Directions

Safety Considerations

Potential Adverse Effects

Mechanistic Safety Concerns

Cross-Disease Rationale

Common Mechanisms

Advantages of RIPK1 Inhibition

Related Pages

References

Related Hypotheses

💬 Discussion